It will be nice to get a PR on this, but I don't think the PR about a date for data will move the share price much. It's the actual data to be released for phase 3 results that will move the share price.
Plus we got many catalysts coming up anyways:
Orphan drug status for GvHD Compassionate use acceptance by FDA phase 2b data at conference in June